Sosei Group Corporation in Japan is to acquire 100% of Activus Pharma Ltd
International biopharmaceutical company Sosei Group Corporation, of Japan, has reached an agreement to acquire 100% of a privately-held biopharmaceutical company Activus Pharma Ltd, based in Chiba, Japan.
Activus Pharma was established in 2006 as a spin-off from DIC Corporation and its core technologies in drug formulation using proprietary nano-particle processing will form the basis of Sosei's new platform technology.
Activus Pure Nano-particle Technology (APNT), unlike other nano-particle processing technologies, keeps compounds virtually free from contamination. At the same time, it can yield pharmaceutical ingredients with particle sizes ranging from 50 to 300nm levels. Thus, APNT enables the development of injections, ophthalmic solutions and inhalations with poorly soluble compounds where high purity is required.
The needs for nano-particle technology within the pharmaceutical industry are still largely unmet. Therefore, the technology can be expected to generate new development candidates for Sosei, and partnership with other pharmaceutical companies will allow Sosei to realise revenue from this technology in a relatively short period of time.